JP6903305B2 - ヒト由来インターロイキン6のsiRNA、組換え発現CAR−Tベクターおよびその構築方法と使用 - Google Patents
ヒト由来インターロイキン6のsiRNA、組換え発現CAR−Tベクターおよびその構築方法と使用 Download PDFInfo
- Publication number
- JP6903305B2 JP6903305B2 JP2019538547A JP2019538547A JP6903305B2 JP 6903305 B2 JP6903305 B2 JP 6903305B2 JP 2019538547 A JP2019538547 A JP 2019538547A JP 2019538547 A JP2019538547 A JP 2019538547A JP 6903305 B2 JP6903305 B2 JP 6903305B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- lentivirus
- cells
- recombinant
- expression vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013598 vector Substances 0.000 title claims description 73
- 108090001005 Interleukin-6 Proteins 0.000 title claims description 49
- 108020004459 Small interfering RNA Proteins 0.000 title claims description 47
- 102000004889 Interleukin-6 Human genes 0.000 title claims description 45
- 229940100601 interleukin-6 Drugs 0.000 title claims description 43
- 238000003259 recombinant expression Methods 0.000 title claims description 15
- 238000010276 construction Methods 0.000 title claims description 6
- 210000004027 cell Anatomy 0.000 claims description 127
- 241000713666 Lentivirus Species 0.000 claims description 86
- 108700010039 chimeric receptor Proteins 0.000 claims description 54
- 239000013612 plasmid Substances 0.000 claims description 53
- 230000014509 gene expression Effects 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 32
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 32
- 239000013604 expression vector Substances 0.000 claims description 29
- 238000004806 packaging method and process Methods 0.000 claims description 27
- 238000013518 transcription Methods 0.000 claims description 25
- 230000035897 transcription Effects 0.000 claims description 24
- 239000006228 supernatant Substances 0.000 claims description 23
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 16
- 238000003776 cleavage reaction Methods 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 230000007017 scission Effects 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 10
- 102000014450 RNA Polymerase III Human genes 0.000 claims description 10
- 108010078067 RNA Polymerase III Proteins 0.000 claims description 10
- 239000013642 negative control Substances 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 9
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 8
- 230000006044 T cell activation Effects 0.000 claims description 8
- 241001492404 Woodchuck hepatitis virus Species 0.000 claims description 8
- 230000005540 biological transmission Effects 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 239000005090 green fluorescent protein Substances 0.000 claims description 8
- 230000000977 initiatory effect Effects 0.000 claims description 8
- 230000001124 posttranscriptional effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 230000006798 recombination Effects 0.000 claims description 7
- 230000010076 replication Effects 0.000 claims description 7
- 239000012228 culture supernatant Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000005215 recombination Methods 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 238000005342 ion exchange Methods 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 4
- 238000000967 suction filtration Methods 0.000 claims description 4
- 102000018697 Membrane Proteins Human genes 0.000 claims description 3
- 108010052285 Membrane Proteins Proteins 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- 208000029824 high grade glioma Diseases 0.000 claims description 2
- 201000011614 malignant glioma Diseases 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims 1
- 239000000047 product Substances 0.000 description 33
- 239000012634 fragment Substances 0.000 description 30
- 239000002609 medium Substances 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 241000700605 Viruses Species 0.000 description 22
- 238000005259 measurement Methods 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 17
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 238000000246 agarose gel electrophoresis Methods 0.000 description 16
- 239000012636 effector Substances 0.000 description 16
- 238000003197 gene knockdown Methods 0.000 description 16
- 108020004999 messenger RNA Proteins 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 239000002158 endotoxin Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 239000011543 agarose gel Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000011084 recovery Methods 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 101150058049 car gene Proteins 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 238000012163 sequencing technique Methods 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 230000002255 enzymatic effect Effects 0.000 description 10
- 230000003584 silencer Effects 0.000 description 10
- 238000012546 transfer Methods 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 238000013461 design Methods 0.000 description 8
- 230000002147 killing effect Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 241000204031 Mycoplasma Species 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 229960003989 tocilizumab Drugs 0.000 description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910021642 ultra pure water Inorganic materials 0.000 description 5
- 239000012498 ultrapure water Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 208000004736 B-Cell Leukemia Diseases 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 4
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 3
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 101710149951 Protein Tat Proteins 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004873 anchoring Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 108091006004 biotinylated proteins Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 230000007783 downstream signaling Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 102000002015 Transforming Protein 1 Src Homology 2 Domain-Containing Human genes 0.000 description 1
- 108010040625 Transforming Protein 1 Src Homology 2 Domain-Containing Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940119059 actemra Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- -1 either CaCl 2 Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000001743 silencing effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4635—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
a. 配列番号43および配列番号44で示されるヌクレオチド配列、
b. 配列番号45および配列番号46で示されるヌクレオチド配列、
c. 配列番号47および配列番号48で示されるヌクレオチド配列、
d. 配列番号49および配列番号50で示されるヌクレオチド配列、
e. 配列番号51および配列番号52で示されるヌクレオチド配列、
f. 配列番号53および配列番号54で示されるヌクレオチド配列、
g. 配列番号55および配列番号56で示されるヌクレオチド配列、
h. 配列番号57および配列番号58で示されるヌクレオチド配列
さらに、b. 配列番号45および配列番号46で示されるヌクレオチド配列がより好ましい。
一.材料
1.レンチウイルス骨格プラスミドpLenti-3G silencer、レンチウイルスパッケージングプラスミドpPac-GP、pPac-Rおよび膜タンパク質プラスミドpEnv-G、HEK293T/17細胞、相同組換え酵素、Oligo Annealing BufferはS&E (Shanghai) BIO-PHARMACEUTICAL TECHNOLOGY CO.,LTD.によって提供された。
EF1α-F:5’-ATTCAAAATTTTATCGATGCTCCGGTGCCCGTCAGT-3’(配列番号25)
EF1α-R:5’-TCACGACACCTGAAATGGAAGA-3’(配列番号26)
CD8 leader-F:5’-GGTGTCGTGAGGATCCGCCACCATGGCCTTACCAGTGACCGC-3’
(配列番号27)
CD8 leader-R:5’-GTGTCATCTGGATGTCCGGCCTGGCGGCGTG-3’(配列番号28)
VL-F:5’-CACGCCGCCAGGCCGGACATCCAGATGACACAGACTACATC-3’(配列番号29)
VL-R:5’-TGTGATCTCCAGCTTGGTCC-3’(配列番号30)
OLC-VH-F:5’-CAAGCTGGAGATCACAGGTGGCGGTGGCTCGGGCGGTGGTGGGTCG
GGTGGCGGCGGATCTGAGGTGAAACTGCAGGAGTCA-3’(配列番号31)
VH-R:5’-TGAGGAGACGGTGACTGAGGT-3’(配列番号32)
CD8 Hinge-F:5’-AGTCACCGTCTCCTCAACCACGACGCCAGCGCC-3’(配列番号33)
CD8 Hinge-R:5’-GTAGATATCACAGGCGAAGTCCA-3’(配列番号34)
CD8 Transmembrane-F:5’-CGCCTGTGATATCTACATCTGGGCGCCCTTGGC-3’(配列番号35)
CD137-F:5’-AAACGGGGCAGAAAGAAACTC-3’(配列番号37)
CD137-R:5’-TGCTGAACTTCACTCTCAGTTCACATCCTCCTTCTTCTTC-3’(配列番号 38)
TCR-F:5’-AGAGTGAAGTTCAGCAGGAGCG-3’(配列番号39)
TCR-R:5’-GGAGAGGGGCGTCGACTTAGCGAGGGGGCAGGGC-3’(配列番号40)
siRNA1761-F(陰性対照):
5’-CCGGTTCTCCGAACGTGTCACGTCTCGAGACGTGACACGTTCGG
AGAATTTTTG-3’(配列番号41)
siRNA1761-R(陰性対照):
5’-AATTCAAAAATTCTCCGAACGTGTCACGTCTCGAGACGTGACAC
GTTCGGAGAA-3’(配列番号42)
siRNA1762-F:5’-CCGGGTGAAGCTGAGTTAATTTATGCTCGAGTAAATTAACTCAGC
TTCACATTTTTTTG-3’(配列番号43)
siRNA1762-R:5’- AATTCAAAAAAATGTGAAGCTGAGTTAATTTACTCGAGCATAAA
TTAACTCAGCTTCAC-3’(配列番号44)
siRNA1763-F:5’-CCGGGCACAGAACTTATGTTGTTCTCTCGAGAACAACATAAGTT
CTGTGCCCTTTTTTG-3’(配列番号45)
siRNA1763-R:5’-AATTCAAAAAAGGGCACAGAACTTATGTTGTTCTCGAGAGAAC
AACATAAGTTCTGTGC-3’(配列番号46)
siRNA1764-F:5’-CCGGCTCAGATTGTTGTTGTTAATGCTCGAGTTAACAACAACAA
TCTGAGGTTTTTTTG-3’(配列番号47)
siRNA1764-R:5’-AATTCAAAAAAACCTCAGATTGTTGTTGTTAACTCGAGCATTAA
CAACAACAATCTGAG-3’(配列番号48)
siRNA1765-F:5’-CCGGGCAGCTTTAAGGAGTTCCTGCCTCGAGAGGAACTCCTTA
AAGCTGCGCTTTTTTG-3’(配列番号49)
siRNA1765-R:5’-AATTCAAAAAAGCGCAGCTTTAAGGAGTTCCTCTCGAGGCAGG
AACTCCTTAAAGCTGC-3’(配列番号50)
siRNA1766-F:5’-CCGGGTGTAGGCTTACCTCAAATAACTCGAGATTTGAGGTAAGC
CTACACTTTTTTTTG-3’(配列番号51)
siRNA1766-R:5’-AATTCAAAAAAAAGTGTAGGCTTACCTCAAATCTCGAGTTATTT
GAGGTAAGCCTACAC-3’(配列番号52)
siRNA1767-F:5’-CCGGCTCAAATAAATGGCTAACTTACTCGAGAGTTAGCCATTTAT
TTGAGGTTTTTTTG-3’(配列番号53)
siRNA1767-R:5’-AATTCAAAAAAACCTCAAATAAATGGCTAACTCTCGAGTAAGTT
AGCCATTTATTTGAG-3’(配列番号54)
siRNA1768-F:5’-CCGGGATGCTTCCAATCTGGATTCACTCGAGAATCCAGATTGGA
AGCATCCATTTTTTG-3’(配列番号55)
siRNA1768-R:5’-AATTCAAAAAATGGATGCTTCCAATCTGGATTCTCGAGTGAATC
CAGATTGGAAGCATC-3’(配列番号56)
siRNA1769-F:5’-CCGGCTTCCAATCTGGATTCAATGACTCGAGATTGAATCCAGAT
TGGAAGCATTTTTTG-3’(配列番号57)
siRNA1769-R:5’-AATTCAAAAAATGCTTCCAATCTGGATTCAATCTCGAGTCATTG
AATCCAGATTGGAAG-3’(配列番号58)
WPRE-QPCR-F:5’-CCTTTCCGGGACTTTCGCTTT-3’(配列番号59)
WPRE-QPCR-R:5’-GCAGAATCCAGGTGGCAACA-3’(配列番号60)
Actin-QPCR-F:5’-CATGTACGTTGCTATCCAGGC-3’(配列番号61)
Actin-QPCR-R:5’-CTCCTTAATGTCACGCACGAT-3’(配列番号62)
CAR-QPCR-F:5’-GACTTGTGGGGTCCTTCTCCT-3’(配列番号63)
CAR-QPCR-R:5’-GCAGCTACAGCCATCTTCCTC-3’(配列番号64)
IL6-QPCR-F:5’-GGATTCAATGAGGAGACTT-3’(配列番号65)
IL6-QPCR-R:5’-ATCTGTTCTGGAGGTACT-3’(配列番号66)
図4を参照すると、本発明に係る組換えレンチウイルスベクターの構築方法は以下の通りである。
一.イオン交換クロマトグラフィーによって組換えレンチウイルスベクターを精製した(図8に示す)。
(1)収集された上清液をThermo真空ポンプで、0.22μm〜0.8μmのPESフィルターで吸引ろ過し、不純物を除去した。
(2)1:1〜1:10の比率で上清に1.5M NaCl 250 mM Tris-HCl(pH 6-8)を入れた。
(4)工程2で得られた溶液をペリスタポンプで1〜10ml/minの速度でイオン交換カラムに仕込んだ。
(5)上清液が全部カラムを通過した後、10ml 0.15M NaCl 25 mM Tris-HCl(pH 6〜8)溶液で1回洗浄した。
(6)仕込み量に応じて1〜5ml 1.5M NaCl 25 mM Tris-HCl(pH 6〜8)で溶離させ、溶離液を収集した。
(7)溶離液を25〜50μl/管で分け、-80℃の冷蔵庫で冷凍保存し、長期間保存した。
(1)24ウェルプレートを取って293T細胞を接種した。各ウェルの細胞は5×104個で、加えられた培地の体積は500μlで、異なる種類の細胞の生長速度は異なり、ウイルス感染時の細胞融合率は40%〜60%であった。
力価(integration units per ml,IU ml-1)の計算式は以下の通りである。
IU ml-1 = (C ×N× D×1000)/V
(1)内毒素使用標準品は15EU/本であった。
(2)ライセート試薬の感度はλ=0.25EU/ml、0.5ml/管であった。
(1)実験前の3日は、細胞サンプルを無抗生物質培地で培養した。
(2)1mlの細胞懸濁液(細胞数は1×105よりも多い)を収集し、1.5ml遠心管に入れた。
(3)13000×gで1min遠心分離し、沈殿を収集し、培地を捨てた。
(4)500μlのPBSをピペットチップで吹きかつ吸いをするかボルテックス振とうし、沈殿を再懸濁させた。13000×gで5min遠心分離した。
(5)工程4を1回繰り返した。
(6)50μlの細胞分解緩衝液を入れ、ピペットチップで吹きかつ吸いをし、十分に混合した後、55℃の水浴で20minインキュベートした。
(7)サンプルを95℃で5min加熱した。
一.CAR遺伝子の細胞レベルの発現測定:
(1)組換えレンチウイルスベクターlvCAR19-1761〜lvCAR19-1769および対照ウイルスMOCKでPBMC細胞に感染させた後、細胞を収集してRT-PCRによってCARのmRNA転写レベルの測定を行い、CAR遺伝子の発現を検証したが、CARのmRNA転写レベルが向上すると、CAR遺伝子の転写レベルの発現に成功したことになる。
(1)それぞれCD19+K562細胞とPBMC細胞を培養した。
(1)それぞれCD19+K562細胞とPBMC細胞を培養した。
殺傷効率= (実験ウェル−エフェクター細胞ウェル−標的細胞ウェル)/(標的細胞最大ウェル−標的細胞ウェル)×100%
Claims (15)
- ヒト由来インターロイキン6のsiRNAであって、配列番号43および配列番号44で示されるヌクレオチド配列の1対であるsiRNA。
- サイトカイン放出症候群を治療・緩和する薬物の製造における請求項1に記載のsiRNAの使用。
- 請求項1に記載のsiRNAを含む組換え発現ベクター。
- 前記発現ベクターは、レンチウイルス発現ベクター、レトロウイルス発現ベクター、アデノウイルス発現ベクター、アデノ随伴ウイルス発現ベクターまたはプラスミドであることを特徴とする請求項3に記載の組換え発現ベクター。
- 前記のレンチウイルス発現ベクターは、配列番号2で示されるプラスミド複製のための原核レプリコンpUC Ori配列、配列番号1で示される目的菌株の大量増幅のためのアンピシリン耐性遺伝子含有AmpR配列、配列番号3で示される真核細胞内における複製を増強するためのウイルスレプリコンSV40 Ori配列、レンチウイルスパッケージングのためのレンチウイルスパッケージングのシスエレメント、配列番号11で示される真核細胞における緑色蛍光タンパク質の発現のためのZsGreen1緑色蛍光タンパク質、配列番号12で示されるタンパク質の共転写発現のためのIRESリボソーム結合配列、配列番号14で示されるキメラ抗原受容体遺伝子の真核転写のためのヒトEF1αプロモーター、配列番号52または配列番号53で示される認識、伝達、開始が一体化した第二世代CARまたは第三世代CARを組み立てるための抗CD19キメラ抗原受容体のコード遺伝子、配列番号13で示される遺伝子組換えの発現効率を増強するためのeWPRE増強型ウッドチャックB型肝炎ウイルス転写後調節エレメント、配列番号14で示される細胞内におけるsiRNAの転写のためのヒトRNAポリメラーゼIIIプロモーターhU6を含むことを特徴とする請求項4に記載の組換え発現ベクター。
- 前記レンチウイルスパッケージングのシスエレメントは、第二世代のレンチウイルスベクターを使用し、配列番号5で示されるレンチウイルス5'末端LTR、配列番号6で示されるレンチウイルス3'末端自己不活性化LTR、配列番号7で示されるGagシスエレメント、配列番号8で示されるRREシスエレメント、配列番号9で示されるenvシスエレメント、配列番号10で示されるcPPTシスエレメントを含むことを特徴とする請求項5に記載の組換え発現ベクター。
- 前記レンチウイルスパッケージングのシスエレメントは、第三世代のレンチウイルスベクターを使用し、配列番号5で示されるレンチウイルス5'末端LTR、配列番号6で示されるレンチウイルス3'末端自己不活性化LTR、配列番号7で示されるGagシスエレメント、配列番号8で示されるRREシスエレメント、配列番号9で示されるenvシスエレメント、配列番号10で示されるcPPTシスエレメント、および配列番号4で示されるRSVプロモーターを含むことを特徴とする請求項5に記載の組換え発現ベクター。
- 前記eWPRE増強型ウッドチャックB型肝炎ウイルス転写後調節エレメントは、6つのヌクレオチドの増強突然変異、具体的には、g.396G>A、g.397C>T、g.398T>C、g.399G>A、g.400A>T、g.411A>Tを有することを特徴とする請求項5に記載の組換え発現ベクター。
- 前記抗CD19キメラ抗原受容体は、順に直列に接続する配列番号16で示されるCD8 leaderキメラ受容体シグナルペプチド、配列番号17で示されるCD19の1本鎖抗体軽鎖VL、配列番号18で示されるOptimal Linker C、配列番号19で示されるCD19の1本鎖抗体重鎖VH、配列番号20で示されるCD8 Hingeキメラ受容体ヒンジ、配列番号21で示されるCD8 Transmembraneキメラ受容体膜貫通領域、配列番号22で示されるCD137キメラ受容体共刺激因子、および配列番号23で示されるTCRキメラ受容体T細胞活性化ドメインを含むことを特徴とする請求項5に記載の組換え発現ベクター。
- 前記抗CD19キメラ抗原受容体は、順に直列に接続する配列番号16で示されるCD8 leaderキメラ受容体シグナルペプチド、配列番号17で示されるCD19の1本鎖抗体軽鎖VL、配列番号18で示されるOptimal Linker C、配列番号19で示されるCD19の1本鎖抗体重鎖VH、配列番号20で示されるCD8 Hingeキメラ受容体ヒンジ、配列番号21で示されるCD8 Transmembraneキメラ受容体膜貫通領域、配列番号24で示されるCD28キメラ受容体共刺激因子、配列番号22で示されるCD137キメラ受容体共刺激因子、および配列番号23で示されるTCRキメラ受容体T細胞活性化ドメインを含むことを特徴とする請求項5に記載の組換え発現ベクター。
- 請求項1に記載のsiRNAを含むレンチウイルス発現ベクターの構築方法であって、
アンピシリン耐性遺伝子含有AmpR配列(配列番号1で示される)、原核レプリコンpUC Ori配列(配列番号2で示される)、ウイルスレプリコンSV40 Ori配列(配列番号3で示される)、レンチウイルスパッケージングのためのレンチウイルスパッケージングのシスエレメント、ZsGreen1緑色蛍光タンパク質(配列番号11で示される)、IRESリボソーム結合配列(配列番号12で示される)、eWPRE増強型ウッドチャックB型肝炎ウイルス転写後調節エレメント(配列番号13で示される)、ヒトRNAポリメラーゼIIIプロモーターhU6(配列番号14で示される)をレンチウイルス骨格プラスミドに組み込む工程(1)と、
ヒトEF1αプロモーター(配列番号15で示される)、認識、伝達、開始が一体化した第二世代CARまたは第三世代CARを組み立てるための抗CD19キメラ抗原受容体を第二世代CARまたは第三世代CARの設計態様に組み立て、酵素切断、連結、組換え反応を経てレンチウイルス骨格プラスミドにクローニングし、第二世代CARまたは第三世代CARの設計の組換えレンチウイルスプラスミドを得る工程(2)と、
上記siRNAおよび配列番号41と配列番号42で示される陰性対照配列を、それぞれ工程(2)で得られた組換えレンチウイルスプラスミドにクローニングし、IL-6ノックダウン組換えレンチウイルスプラスミドを得る工程(3)と、
工程(3)で得られた組換えレンチウイルスプラスミドをそれぞれレンチウイルスパッケージングプラスミドおよび膜タンパク質プラスミドとHEK293T/17細胞に共形質移入させ、HEK293T/17細胞において遺伝子の転写・発現を行わせた後、パッケージングに成功した組換えレンチウイルスベクターが細胞培養上清に放出され、組換えレンチウイルスベクターを含む上清液を収集する工程(4)と、
得られた組換えレンチウイルス上清は、吸引ろ過、吸着、溶離のイオン交換手段によって精製し、それぞれ組換えレンチウイルスベクターを得る工程(5)と、
を含む構築方法。 - 工程(4)において、前記吸引ろ過ステップは、上清体積を200ml〜2000mlに、真空度を-0.5MPA〜-0.9MPAに抑え、穴詰まりによるベクターの損失を防ぎ、前記吸着ステップは、溶液のpH値を6〜8に抑え、pHの変化によるベクターの不活性化を防止し、前記溶離ステップは溶離液のイオン強度を0.5M〜1.0Mに抑え、イオン強度の変化による溶離の不完全またはベクターの不活性化を防ぐことを特徴とする請求項11に記載の構築方法。
- CAR-T治療過程におけるIL-6の放出によるサイトカイン放出症候群の薬物の製造における請求項3〜10のいずれか一項に記載の組換え発現ベクターの使用。
- 請求項3に記載の請求項1に記載のsiRNAを含む組換え発現ベクターにより形質移入されたT細胞である、CAR-T細胞。
- Bリンパ腫、膵臓腺癌、脳膠細胞腫、骨髄腫の治療薬の製造における請求項14に記載のCAR-T細胞の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610887703.XA CN106636090B (zh) | 2016-10-11 | 2016-10-11 | 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用 |
CN201610887703.X | 2016-10-11 | ||
PCT/CN2016/105263 WO2018068354A1 (zh) | 2016-10-11 | 2016-11-10 | 人源白细胞介素 6 的 siRNA 、重组表达 CAR-T 载体及其构建方法和应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020097492A Division JP6996779B2 (ja) | 2016-10-11 | 2020-06-04 | ヒト由来インターロイキン6のsiRNA、組換え発現CAR-Tベクターおよびその構築方法と使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019532673A JP2019532673A (ja) | 2019-11-14 |
JP6903305B2 true JP6903305B2 (ja) | 2021-07-14 |
Family
ID=58855172
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019538547A Active JP6903305B2 (ja) | 2016-10-11 | 2016-11-10 | ヒト由来インターロイキン6のsiRNA、組換え発現CAR−Tベクターおよびその構築方法と使用 |
JP2020097492A Active JP6996779B2 (ja) | 2016-10-11 | 2020-06-04 | ヒト由来インターロイキン6のsiRNA、組換え発現CAR-Tベクターおよびその構築方法と使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020097492A Active JP6996779B2 (ja) | 2016-10-11 | 2020-06-04 | ヒト由来インターロイキン6のsiRNA、組換え発現CAR-Tベクターおよびその構築方法と使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10702552B2 (ja) |
EP (1) | EP3505629A4 (ja) |
JP (2) | JP6903305B2 (ja) |
KR (1) | KR102266755B1 (ja) |
CN (1) | CN106636090B (ja) |
WO (1) | WO2018068354A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108148863B (zh) * | 2016-12-05 | 2019-12-17 | 上海优卡迪生物医药科技有限公司 | 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用 |
CN107245500B (zh) * | 2017-05-27 | 2019-05-17 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用 |
JP2020537528A (ja) * | 2017-10-19 | 2020-12-24 | セレクティスCellectis | 改善された免疫細胞療法のためのnk阻害物質遺伝子の標的指向遺伝子組み込み |
CN107916269B (zh) * | 2017-11-17 | 2020-12-11 | 山东兴瑞生物科技有限公司 | 靶向cd19的tcr基因、制备方法、具有该基因的质粒、试剂盒及应用 |
CN108753774B (zh) * | 2018-05-03 | 2021-03-30 | 山东省齐鲁细胞治疗工程技术有限公司 | 干扰il-6表达的cd19-car-t细胞及其应用 |
JP2021525530A (ja) * | 2018-06-01 | 2021-09-27 | ワシントン・ユニバーシティWashington University | キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制 |
CN108949759B (zh) * | 2018-07-23 | 2021-06-01 | 合肥一兮生物科技有限公司 | 敲减人IL-15的siRNA、CD19 CAR表达载体、CAR-T细胞及构建方法和应用 |
CN110317808B (zh) * | 2019-06-10 | 2022-11-18 | 纳肽得(青岛)生物医药有限公司 | 肝细胞癌相关基因的siRNA分子及其应用 |
CN112430579A (zh) * | 2019-08-26 | 2021-03-02 | 深圳宾德生物技术有限公司 | 靶向Her2并干扰IL-6表达的嵌合抗原受体T细胞及其制备方法和应用 |
CN112430577A (zh) * | 2019-08-26 | 2021-03-02 | 深圳宾德生物技术有限公司 | 靶向EGFRvⅢ并干扰IL-6表达的嵌合抗原受体T细胞及其制备方法和应用 |
TWI758171B (zh) | 2021-04-28 | 2022-03-11 | 沛爾生技醫藥股份有限公司 | 慢病毒包裝系統及使用其以提高宿主細胞之慢病毒產量的方法 |
US12006353B2 (en) | 2022-07-25 | 2024-06-11 | Long Chen | Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof |
CN117402902B (zh) * | 2023-12-11 | 2024-04-16 | 温氏食品集团股份有限公司 | 引物组合物及其在制备t载体上的应用 |
CN117567650B (zh) * | 2024-01-15 | 2024-04-02 | 中国人民解放军东部战区总医院 | 共表达细胞间黏附分子icam2的car-t细胞及其制备方法与应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004010547A1 (de) * | 2004-03-03 | 2005-11-17 | Beiersdorf Ag | Oligoribonukleotide zur Behandlung von irritativen und/oder entzündlichen Hauterscheinungen durch RNA-Interferenz |
US20070036773A1 (en) * | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
JP2009518008A (ja) * | 2005-11-30 | 2009-05-07 | イントラディグム コーポレイション | 遺伝子発現をノックダウンするため、そして固形臓器および細胞の移植を改善するためにsiRNAを使用する組成物および方法 |
WO2007079224A2 (en) * | 2005-12-30 | 2007-07-12 | Wei-Wu He | Sirna compositions promoting scar-free wound healing of skin and methods for wound treatment |
WO2008109350A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting il6 gene expression and uses thereof |
ES2859522T3 (es) * | 2012-07-13 | 2021-10-04 | Univ Pennsylvania | Control de la toxicidad para la actividad antitumoral de CAR |
JP6853514B2 (ja) * | 2015-12-27 | 2021-03-31 | 国立大学法人東海国立大学機構 | 炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球 |
CN105602992B (zh) * | 2016-03-17 | 2019-06-21 | 上海优卡迪生物医药科技有限公司 | 一种基于复制缺陷性重组慢病毒的car-t转基因载体及其构建方法和应用 |
-
2016
- 2016-10-11 CN CN201610887703.XA patent/CN106636090B/zh active Active
- 2016-11-10 KR KR1020197007212A patent/KR102266755B1/ko active IP Right Grant
- 2016-11-10 WO PCT/CN2016/105263 patent/WO2018068354A1/zh unknown
- 2016-11-10 US US16/331,142 patent/US10702552B2/en active Active
- 2016-11-10 EP EP16918621.0A patent/EP3505629A4/en active Pending
- 2016-11-10 JP JP2019538547A patent/JP6903305B2/ja active Active
-
2020
- 2020-06-04 JP JP2020097492A patent/JP6996779B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP3505629A1 (en) | 2019-07-03 |
JP2019532673A (ja) | 2019-11-14 |
KR102266755B1 (ko) | 2021-06-23 |
CN106636090B (zh) | 2019-08-09 |
JP2020188777A (ja) | 2020-11-26 |
EP3505629A4 (en) | 2020-01-01 |
US10702552B2 (en) | 2020-07-07 |
JP6996779B2 (ja) | 2022-02-15 |
US20190201445A1 (en) | 2019-07-04 |
CN106636090A (zh) | 2017-05-10 |
KR20190038645A (ko) | 2019-04-08 |
WO2018068354A1 (zh) | 2018-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6996779B2 (ja) | ヒト由来インターロイキン6のsiRNA、組換え発現CAR-Tベクターおよびその構築方法と使用 | |
JP6930762B2 (ja) | ヒトPD−1をノックダウンしたsiRNA、組換え発現CAR−Tベクターおよびその構築方法と使用 | |
JP6783009B2 (ja) | Il6rがブロッキングされたcrsを緩和するためのcar−t遺伝子組換えベクターおよびその構築方法と使用 | |
JP6736109B2 (ja) | Pdl1がブロッキングされた免疫逃避を抑制するためのcar−t遺伝子組換えベクターおよびその構築方法と使用 | |
WO2018223600A1 (zh) | Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用 | |
CN106967685B (zh) | 共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途 | |
JP2021138721A (ja) | Hiv予備免疫化および免疫療法 | |
JP2024045608A (ja) | 制御性rnaを発現させるためのベクターシステム | |
WO2018223601A1 (zh) | 基于octs-car的抗psca及pdl1双靶向嵌合抗原受体、编码基因及表达载体 | |
CN112048481B (zh) | 一种靶向cd19的嵌合抗原受体nk细胞及其应用 | |
CN108342363B (zh) | 共表达抗msln嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途 | |
WO2018218877A1 (zh) | 一种基于octs技术的恶性胶质瘤car-t治疗载体及其构建方法和应用 | |
WO2017120998A1 (zh) | 治疗脑胶质母细胞瘤的治疗组合物 | |
CN108342361B (zh) | 治疗间质素阳性肿瘤的治疗组合物 | |
CN107034193B (zh) | 治疗b细胞白血病及b细胞淋巴瘤的治疗组合物 | |
WO2018218879A1 (zh) | 一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用 | |
CN107523569B (zh) | Pdcd1基因的用途及其相关药物 | |
WO2018218878A1 (zh) | 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用 | |
WO2018218875A1 (zh) | 一种基于octs技术的前列腺癌car-t治疗载体及其构建方法和应用 | |
CN112521515B (zh) | Cd19和cd10双靶点嵌合抗原受体及其应用 | |
CN111235151A (zh) | 一种CXCR4基因的shRNA及其应用 | |
CN113736780A (zh) | 一种敲除p300基因的BCBL1细胞系及其构建方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200604 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20201117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210316 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210316 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210416 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210420 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210615 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210615 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6903305 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |